Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 37390310

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2023 Aug 24
First author
Seymour JF

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2023 Aug 24;142(8):679-680. doi: 10.1182/blood.2023020974.
    note
    Source null
    related pmid
    37616021
    relationship
    Comment in
  2. citation
    Expert Rev Hematol. 2023 Jul-Dec;16(11):803-806. doi: 10.1080/17474086.2023.2271170.
    note
    Source null
    related pmid
    37830359
    relationship
    Comment in

Authors and identifiers

  1. name
    Seymour JF
    type
    Author
  2. name
    Byrd JC
    type
    Author
  3. name
    Ghia P
    type
    Author
  4. name
    Kater AP
    type
    Author
  5. name
    Chanan-Khan A
    type
    Author
  6. name
    Furman RR
    type
    Author
  7. name
    O'Brien S
    type
    Author
  8. name
    Brown JR
    type
    Author
  9. name
    Munir T
    type
    Author
  10. name
    Mato A
    type
    Author
  11. name
    Stilgenbauer S
    type
    Author
  12. name
    Bajwa N
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Seymour JF
    type
    Author
  2. name
    Byrd JC
    type
    Author
  3. name
    Ghia P
    type
    Author
  4. name
    Kater AP
    type
    Author
  5. name
    Chanan-Khan A
    type
    Author
  6. name
    Furman RR
    type
    Author
  7. name
    O'Brien S
    type
    Author
  8. name
    Brown JR
    type
    Author
  9. name
    Munir T
    type
    Author
  10. name
    Mato A
    type
    Author
  11. name
    Stilgenbauer S
    type
    Author
  12. name
    Bajwa N
    type
    Author
bibliography ids
  1. nci-bib-ea2ee009b363db5b11f384b0
book metadata
content sha256
5fdf16e992627b27e6e8c5cfe3f94e27160fb06b894ed2d04c0eaeb8bb90a6cc
document type
citation
dois
  1. 10.1182/blood.2022018818
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:37390310
immutable id
pubmed:37390310@5fdf16e992627b27e6e8c5cfe3f94e27160fb06b894ed2d04c0eaeb8bb90a6cc
journal
abbreviation
Blood
issn electronic
1528-0020
issn print
0006-4971
issue
8
name
Blood
nlm unique id
7603509
pages
687-699
volume
142
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2023 Aug 24;142(8):679-680. doi: 10.1182/blood.2023020974.
    note
    Source null
    related pmid
    37616021
    relationship
    Comment in
  2. citation
    Expert Rev Hematol. 2023 Jul-Dec;16(11):803-806. doi: 10.1080/17474086.2023.2271170.
    note
    Source null
    related pmid
    37830359
    relationship
    Comment in
outcomes validated
false
pmid
37390310
provenance
batch id
5329a5d0877ee70ecd11
provider
NCBI PubMed ESummary
record sha256
4a3d2caa336459d5ff684b73b487d27654803c849c5616242675a79f561ebccb
response sha256
bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
retrieved at
2026-09-09T23:48:15.763286+00:00
publication date
display
2023 Aug 24
precision
day
year
2023
publication types
  1. Clinical Trial
  2. Journal Article
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/37390310/
title
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.

Preserved source evidence · Not medical advice